MedTrace Logo

Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.

NCT01231828 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2013-02-27

No results posted yet for this study

Summary

The project will improve scientific knowledge regarding a recent law applying potentially to every french driver. It will give for the first time an indication on the impact of alerting treatments on driving risks. It will reinforce the links between different research environments (sleep physiopathology, clinical research, cognitive neurosciences, drivers supervision, virtual reality, pharmacology) among the "Réseau Eveil Sommeil Attention et Transports" (RESAT) network.

Conditions

  • Cirrhosis

Interventions

DRUG

L-carnitine

L-carnitine 4g per day (4 bottles of 10ml).

DRUG

Lactulose

Lactulose (30-60 ml per day)

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Marie-Astrid PIQUET · University Hospital, Caen

  • Thong DAO · University Hospital, Caen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-06-30
Completion
2012-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231828 on ClinicalTrials.gov